newsfilter
← Latest News
PR Newswire·

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

  • VolitionRx Limited announced financial results and a business update for the second quarter of 2026.
  • A conference call to discuss results is scheduled for Friday, August 14, 2026, at 8:30 a.m. U.S. Eastern Time.
  • Management is in discussions with over a dozen diagnostic companies to secure licensing agreements & revenue from milestones or royalties.
  • A collaboration was announced with Sysmex Corporation regarding Neutrophil Extracellular Traps (NETS).
  • A clinical manuscript on the Nu.Q® Vet feline prototype for detecting lymphoma was submitted for peer review, potentially unlocking a $5 million milestone payment.
  • Reimbursement submission for Nu.Q® Lung Cancer is ongoing with Hospices Civils de Lyon.
  • First peer-reviewed paper demonstrating Capture-Seq™ liquid biopsy technology was published.
  • Total Addressable Markets (TAM) for all product pillars are estimated at over $27 billion annually.
  • First half of 2026 revenue reached $1.4 million, representing 112% growth over the first half of 2025.
  • Second quarter 2026 revenue was approximately $0.4 million, consistent with the same period in 2025.
  • Operating expenses in the second quarter of 2026 were 32% lower than the same quarter in 2025 due to cost reduction efforts.
  • Operating loss for the second quarter of 2026 was $4.2 million, a 34% decrease compared to the prior year period.
  • Net cash used in operating activities was $5.2 million in the second quarter of 2026, down 18% from the previous year.
  • Second quarter receipts included $1.2 million from equity sales via an at-the-market facility & $4.1 million from a confidentially marketed public offering.
  • The conference call will be hosted by Louise Batchelor, Cameron Reynolds, & Terig Hughes.
  • A live audio webcast & telephone replay of the call will be available until August 28, 2026.